Publicacions destacades

• Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions

  Autors: Moore C; Stöhr W; Crook A; Richert L; Leliévre J; Pantaleo G; García F; Vella S; Lévy Y; Thiébaut R; McCormack S.

  Referència: THE LANCET HIV 2019; 6(5):e334-e340.

• Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

  Autors: Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL, European Network for AIDS Treatment 022 (NEAT022) Study Group.

  Referència: CLINICAL INFECTIOUS DISEASES 2019; 68(4):597-606.

• Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

  Autors: Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, de la Rosa G, Rimola A, Miro JM, FIPSE LT-HIV investigators.

  Referència: AMERICAN JOURNAL OF TRANSPLANTATION 2018; 18(10):2513-2522.

• Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

  Autors: Berenguer J., Rodríguez-Castellano E., Carrero A., Von Wichmann M.A., Montero M., Galindo M.J., Mallolas J., Crespo M., Téllez M.J., Quereda C., Sanz J., Barros C., Tural C., Santos I., Pulido F., Guardiola J.M., Rubio R., Ortega E., Montes M.L., Jusdado J.J., Gaspar G., Esteban H., Bellón J.M., González-García J..

  Referència: HEPATOLOGY 2017; 66(2):344-356.

• HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma

  Autors: Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-Cisneros J, Gonzalez-Dieguez L, Salcedo M, Serrano T, Jimenez-Perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM, FIPSE Investigators.

  Referència: HEPATOLOGY 2016; 63(2):488-498.

• Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study (vol 62, pg 92, 2015)

  Autors: Castells, Lluis; Rimola, Antoni; Manzardo, Christian; Valdivieso, Andres; Luis Montero, Jose; Barcena, Rafael; Abradelo, Manuel; Xiol, Xavier; Aguilera, Victoria; Salcedo, Magdalena; Rodriguez, Manuel; Bernal, Carmen; Suarez, Francisco; Antela, Antonio; Olivares, Sergio; del Campo, Santos; Laguno, Montserrat; Fernandez, Jose R; de la Rosa, Gloria; Agueero, Fernando; Perez, Inaki; Gonzalez-Garcia, Juan; Esteban-Mur, Juan I; Miro, Jose M;FIPSE LT-HIV Investigators.

  Referència: JOURNAL OF HEPATOLOGY 2016; 64(3):757-757.

• Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial

  Autors: Martinez, Esteban; Gonzalez-Cordon, Ana; Ferrer, Elena; Domingo, Pere; Negredo, Eugenia; Gutierrez, Felix; Portilla, Joaquin; Curran, Adria; Podzamczer, Daniel; Ribera, Esteban; Murillas, Javier; Bernardino, Jose I; Santos, Ignacio; Carton, Jose A; Peraire, Joaquim; Pich, Judit; Deulofeu, Ramon; Perez, Ignacio; Gatell, Jose M;ATADAR Study Grp.

  Referència: CLINICAL INFECTIOUS DISEASES 2015; 60(5):811-820.

• Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults

  Autors: Egana-Gorrono, L; Martinez, E; Perez, I; Escriba, T; Domingo, P; Gatell, J M; Arnedo, M.

  Referència: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2014; 69(11):3076-3084.

• A dendritic cell-based vaccine elicits T cell responses associated with control 1 replication

  Autors: Garcia, Felipe; Climent, Nuria; Guardo, Alberto C; Gil, Cristina; Leon, Agathe; Autran, Brigitte; Lifson, Jeffrey D; Martinez-Picado, Javier; Dalmau, Judit; Clotet, Bonaventura; Gatell, Josep M; Plana, Montserrat; Gallart, Teresa.

  Referència: SCIENCE TRANSLATIONAL MEDICINE 2013; 5(166):166ra2-166ra2.

• Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis (virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

  Autors: Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis; Slim, Jihad; Rivero, Antonio; Mak, Carmen; Thompson, Seth; Howe, Anita Y M; Wenning, Larissa; Sklar, Peter; Wahl, Janice; Greaves, Wayne;P05411 Study Investigators.

  Referència: LANCET INFECTIOUS DISEASES, THE 2013; 13(7):597-605.